NEW YORK, Sept. 15, 2008 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, today announced that it has received the third year of grant funding for its ongoing Lassa fever antiviral research. This award provides an additional $3,655,000 from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), on top of the $2,089,000 in funding that SIGA has already received from this grant.
